MedCity News
MAY 19, 2024
Carter entered hospice care in his home, more than a year ago, and has set an inspirational example of how to live your last days on Earth with hope, meaning, and vigor. The post The Powerful Hospice Lessons of Jimmy Carter appeared first on MedCity News.
Pharmaceutical Technology
MAY 19, 2024
Discover what industry professionals seek in contract manufacturing for parenteral solutions. Ensure quality, compliance, and innovation with our comprehensive guide. Click to learn more.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
MAY 19, 2024
Employers are in a unique position to drive change in obesity care, but face several challenges. Experts shared numerous strategies employers can implement. The post ‘The Time Is Now’: How Employers Can Offer Comprehensive Obesity Care appeared first on MedCity News.
Pharmaceutical Technology
MAY 19, 2024
Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction.
MedCity News
MAY 19, 2024
Saint Luke’s Mid America Heart Institute launched a new solution on its care platform to help patients who have AFib or are at risk of developing the condition. The program, which was developed with digital health startup Story Health, seeks to engage patients between clinic visits. The post Saint Luke’s, Story Health Roll Out New AFib Program appeared first on MedCity News.
Pharmaceutical Technology
MAY 19, 2024
Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Pancreatic Ductal Adenocarcinoma.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmaceutical Technology
MAY 19, 2024
Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Metastatic Biliary Tract Cancer.
MedCity News
MAY 19, 2024
Rapport Therapeutics’ lead program could offer more targeted epilepsy treatment compared to currently available anti-seizure medications, which introduce many side effects. The IPO will support plans to develop the oral small molecule in focal epilepsy as well as chronic pain and bipolar disorder. The post CNS-Focused Rapport Therapeutics Preps IPO to Back Phase 2-Ready Epilepsy Drug appeared first on MedCity News.
Pharmaceutical Technology
MAY 19, 2024
Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Metastatic Pancreatic Cancer.
Pharmacy Times
MAY 19, 2024
Researchers observed that patients aged 80 years and older with acute myeloid leukemia who were treated with venetoclax and a hypomethylating agent had prolonged overall survival.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmaceutical Technology
MAY 19, 2024
Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Renal Cell Carcinoma.
Pharmaceutical Technology
MAY 19, 2024
Olverembatinib is under clinical development by Ascentage Pharma Group International and currently in Phase II for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia).
Pharmaceutical Technology
MAY 19, 2024
Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma).
Pharmaceutical Technology
MAY 19, 2024
Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction.
Pharmaceutical Technology
MAY 19, 2024
Furmonertinib mesylate is under clinical development by Shanghai Allist Pharmaceuticals and currently in Phase II for Lung Adenocarcinoma.
Pharmaceutical Technology
MAY 19, 2024
Elixcyte is under clinical development by Unicocell Biomed and currently in Phase II for Chronic Kidney Disease (Chronic Renal Failure).
Pharmaceutical Technology
MAY 19, 2024
Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Neuroblastoma.
Pharmaceutical Technology
MAY 19, 2024
Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Osteosarcoma.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Pharmaceutical Technology
MAY 19, 2024
Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Pancreatic Ductal Adenocarcinoma.
Pharmaceutical Technology
MAY 19, 2024
Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Metastatic Biliary Tract Cancer.
Pharmaceutical Technology
MAY 19, 2024
Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Metastatic Pancreatic Cancer.
Pharmaceutical Technology
MAY 19, 2024
Vusolimogene oderparepvec is under clinical development by Replimune and currently in Phase II for Metastatic Melanoma.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
MAY 19, 2024
Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Malignant Mesothelioma.
Pharmaceutical Technology
MAY 19, 2024
Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Renal Cell Carcinoma.
Pharmaceutical Technology
MAY 19, 2024
Dipraglurant is under clinical development by Addex Therapeutics and currently in Phase II for Blepharospasm.
Pharmaceutical Technology
MAY 19, 2024
Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Cervical Cancer.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Pharmaceutical Technology
MAY 19, 2024
PLX-038 is under clinical development by ProLynx and currently in Phase II for Recurrent Medulloblastoma.
Pharmaceutical Technology
MAY 19, 2024
SkinTE is under clinical development by RegenETP and currently in Phase III for Diabetic Foot Ulcers.
Pharmaceutical Technology
MAY 19, 2024
PLX-038 is under clinical development by ProLynx and currently in Phase II for Ependymoma.
Expert insights. Personalized for you.
126 
Let's personalize your content